Paul J. Meis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul J. Meis has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Atef H. Moawad
3 shared publications- Alan M. Peaceman
Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
2 shared publications Alicia Aleman
Department of Obstetrics and Gynecology, Wake Forest University School of Medicine, Winston-Salem, USA
2 shared publicationsBrian Mercer
2 shared publicationsDeborah Conway
2 shared publicationsJay D. Iams
2 shared publications
Latest Publications
- RetractionOpen Access
- 22 August 2025
- Published by Springer Nature in Drugs
- Vol. 85 (10) , 1335
Retraction Note: Progesterone Treatment to Prevent Preterm Birth
- 22 August 2025
- Published by Springer Nature in Drugs
- Vol. 85 (10) , 1335
RetractionOpen AccessRetraction Note: Progesterone Treatment to Prevent Preterm Birth
- Open Access
- 1 November 2006
- Published by SAGE Publications in Women's Health
- Vol. 2 (6) , 819-824
The Role of 17 α-Hydroxyprogesterone Caproate in the Prevention of Preterm Birth
Preterm birth is a major public-health problem in the USA, which has higher rates of preterm birth than most other developed countries. Attempts at the prevention of preterm birth have been largely unsuccessful. The recent publication of a large, multicenter, randomized trial of 17 α-hydroxyprogesterone caproate, which showed efficacy in preventing recurrent preterm delivery, has sparked renewed interest in progestational drugs in general and this compound in particular for use in preventing preterm delivery. Although this drug is not currently commercially available, an application has been made to the US FDA to produce 17 α-hydroxyprogesterone caproate, as Gestiva™ for the prevention of preterm delivery.
- 1 November 2006
- Published by SAGE Publications in Women's Health
- Vol. 2 (6) , 819-824
Open AccessThe Role of 17 α-Hydroxyprogesterone Caproate in the Prevention of Preterm Birth
Preterm birth is a major public-health problem in the USA, which has higher rates of preterm birth than most other developed countries. Attempts at the prevention of preterm birth have been largely unsuccessful. The recent publication of a large, multicenter, randomized trial of 17 α-hydroxyprogesterone caproate, which showed efficacy in preventing recurrent preterm delivery, has sparked renewed interest in progestational drugs in general and this compound in particular for use in preventing preterm delivery. Although this drug is not currently commercially available, an application has been made to the US FDA to produce 17 α-hydroxyprogesterone caproate, as Gestiva™ for the prevention of preterm delivery.
- 1 September 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 106 (3) , 557-561
Does Progesterone Treatment Influence Risk Factors for Recurrent Preterm Delivery?
To examine how demographic and pregnancy characteristics can affect the risk of recurrent preterm delivery and the how the effectiveness of progesterone treatment for prevention alters these relationships. This was a secondary analysis of a randomized trial of 17alpha-hydroxyprogesterone caproate to prevent recurrent preterm delivery in women at risk. Associations of risk factors for preterm delivery (less than 37 completed weeks of gestation) were examined separately for the women in the 17alpha-hydroxyprogesterone caproate (n = 310) and placebo (n = 153) groups. Univariate analysis found that the number of previous preterm deliveries and whether the penultimate delivery was preterm were significant risk factors for preterm delivery in both the placebo and progesterone groups. High body mass index was protective of preterm birth in the placebo group. Multivariate analysis found progesterone treatment to cancel the risk of more than 1 previous preterm delivery, but not the risk associated with the penultimate pregnancy delivered preterm. Obesity was associated with lower risk for preterm delivery in the placebo group but not in the women treated with progesterone. The use of 17alpha-hydroxyprogesterone caproate in women with a previous preterm delivery reduces the overall risk of preterm delivery and changes the epidemiology of risk factors for recurrent preterm delivery. In particular, these data suggest that 17alpha-hydroxyprogesterone caproate reduces the risk of a history of more than 1 preterm delivery. I.
- 1 September 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 106 (3) , 557-561
Does Progesterone Treatment Influence Risk Factors for Recurrent Preterm Delivery?
To examine how demographic and pregnancy characteristics can affect the risk of recurrent preterm delivery and the how the effectiveness of progesterone treatment for prevention alters these relationships. This was a secondary analysis of a randomized trial of 17alpha-hydroxyprogesterone caproate to prevent recurrent preterm delivery in women at risk. Associations of risk factors for preterm delivery (less than 37 completed weeks of gestation) were examined separately for the women in the 17alpha-hydroxyprogesterone caproate (n = 310) and placebo (n = 153) groups. Univariate analysis found that the number of previous preterm deliveries and whether the penultimate delivery was preterm were significant risk factors for preterm delivery in both the placebo and progesterone groups. High body mass index was protective of preterm birth in the placebo group. Multivariate analysis found progesterone treatment to cancel the risk of more than 1 previous preterm delivery, but not the risk associated with the penultimate pregnancy delivered preterm. Obesity was associated with lower risk for preterm delivery in the placebo group but not in the women treated with progesterone. The use of 17alpha-hydroxyprogesterone caproate in women with a previous preterm delivery reduces the overall risk of preterm delivery and changes the epidemiology of risk factors for recurrent preterm delivery. In particular, these data suggest that 17alpha-hydroxyprogesterone caproate reduces the risk of a history of more than 1 preterm delivery. I.
- 1 May 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 105 (5, Part 1) , 1128-1135
17 Hydroxyprogesterone for the Prevention of Preterm Delivery
The recent publication of 2 large randomized trials of 17 alpha hydroxyprogesterone caproate (17P) and progesterone suppositories, respectively, for the prevention of premature labor have renewed interest in the use of progesterone to prevent preterm birth. The results of these trials have reinforced the positive results of earlier smaller trials of 17P to prevent preterm delivery. A large body of evidence attests to the lack of teratogenic effects of 17P in pregnancy. Although progesterone is known to have many actions beneficial to the maintenance of pregnancy, the exact mode of action of 17P therapy in preventing preterm labor and delivery is not known. Current evidence supports the use of 17P treatment, begun early in the second trimester of gestation and continued weekly until 36 weeks, for women with a history of a previous spontaneous preterm delivery. At present no evidence exists for the use of 17P to prevent preterm delivery in women with multiple gestation, a short uterine cervix, or other high-risk conditions. The use of 17P or other progestins should not be encouraged for these indications outside of randomized trials. At present no evidence exists for the efficacy of any oral progesterone compound in preventing preterm labor. Four trials reporting the use of a progestational drug in patients with symptoms of preterm labor found no efficacy in prolonging pregnancy, and the use of 17P or other progestational drugs as tocolytic therapy should not be encouraged.
- 1 May 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 105 (5, Part 1) , 1128-1135
17 Hydroxyprogesterone for the Prevention of Preterm Delivery
The recent publication of 2 large randomized trials of 17 alpha hydroxyprogesterone caproate (17P) and progesterone suppositories, respectively, for the prevention of premature labor have renewed interest in the use of progesterone to prevent preterm birth. The results of these trials have reinforced the positive results of earlier smaller trials of 17P to prevent preterm delivery. A large body of evidence attests to the lack of teratogenic effects of 17P in pregnancy. Although progesterone is known to have many actions beneficial to the maintenance of pregnancy, the exact mode of action of 17P therapy in preventing preterm labor and delivery is not known. Current evidence supports the use of 17P treatment, begun early in the second trimester of gestation and continued weekly until 36 weeks, for women with a history of a previous spontaneous preterm delivery. At present no evidence exists for the use of 17P to prevent preterm delivery in women with multiple gestation, a short uterine cervix, or other high-risk conditions. The use of 17P or other progestins should not be encouraged for these indications outside of randomized trials. At present no evidence exists for the efficacy of any oral progesterone compound in preventing preterm labor. Four trials reporting the use of a progestational drug in patients with symptoms of preterm labor found no efficacy in prolonging pregnancy, and the use of 17P or other progestational drugs as tocolytic therapy should not be encouraged.
- 1 December 2004
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 47 (4) , 784-795
Progesterone Treatment to Prevent Preterm Birth
- 1 December 2004
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 47 (4) , 784-795
Progesterone Treatment to Prevent Preterm Birth
- Retracted
- 1 January 2004
- Published by Springer Nature in Drugs
- Vol. 64 (21) , 2463-2474
Progesterone Treatment to Prevent Preterm Birth
- 1 January 2004
- Published by Springer Nature in Drugs
- Vol. 64 (21) , 2463-2474
RetractedProgesterone Treatment to Prevent Preterm Birth
- Top Cited PapersOpen Access
- 12 June 2003
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (24) , 2379-2385
Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate
Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery.
- 12 June 2003
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (24) , 2379-2385
Top Cited PapersOpen AccessPrevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate
Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery.
- 1 May 1998
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 53 (5) , 262-263
Antibiotic Therapy for Reduction of Infant Morbidity After Preterm Premature Rupture of the Membranes
- 1 May 1998
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 53 (5) , 262-263
Antibiotic Therapy for Reduction of Infant Morbidity After Preterm Premature Rupture of the Membranes